LIXTE BIOTECHNOLOGY HOLDINGS, INC. Business Operations Contracts & Agreements
9 Contracts & Agreements
- Advisory Agreements (1 contract)
- Collaboration Agreements (2)
- Development Agreements (1)
- Sales Agreements (1)
- Services Agreements (3)
- Termination Agreements (1)
- Termination letter between H. Lee Moffitt Cancer Center and Research Institute, Inc. and the Company dated October 4, 2023 and effective as of September 30, 2023 (Filed With SEC on November 9, 2023)
- Amendment No. 1 to Development Collaboration Agreement by and between Lixte Biotechnology Holdings, Inc and the Netherlands Cancer Institute, Amsterdam, and the Oncode Institute,... (Filed With SEC on November 9, 2023)
- Amendment 2 to Development Collaboration Agreement (certain portions of this Exhibit have been omitted) (Filed With SEC on October 17, 2023)
- Sales Agreement dated as of September 20, 2021 between Lixte Biotechnology Holdings, Inc. and WestPark Capital, Inc (Filed With SEC on September 20, 2021)
- Master Service Agreement with Foundation of Angelman Syndrome Therapeutics FAST (Filed With SEC on August 18, 2020)
- ADVISORY AGREEMENT (Filed With SEC on March 21, 2014)
- NATIONAL INSTITUTES OF HEALTH MATERIALS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on March 21, 2014)
- PUBLICHEALTH SERVICE PATENTLICENSE AGREEMENT EXCLUSIVE COVERPAGE (Filed With SEC on March 31, 2009)
- SERVICES AGREEMENT between LIXTE BIOTECHNOLOGY, INC. and Freestate of Bavaria Represented by UNIVERSITY OF REGENSBURG for its Institute of Pathology, Franz-Josef-Strauss-Alle 11,... (Filed With SEC on January 11, 2007)
